About Immutrix Therapeutics
Immutrix Therapeutics is a company based in Rapid City (United States) founded in 2009 by Carol Rae. Immutrix Therapeutics has raised $14.02 million across 6 funding rounds. Immutrix Therapeutics offers products and services including Blood-Cleansing Device and Extracorporeal System. Immutrix Therapeutics operates in a competitive market with competitors including Haemonetics, Vetex Medical, MediSieve, Hemostasis and Immunocept Medical Products, among others.
- Headquarter Rapid City, United States
- Founders Carol Rae
- SectorsHealthcare
- Phone•••• ••••
- Website immutrix.com
- Legal Name Immutrix Therapeutics, Inc.
- Total Equity Funding$14.02M (USD)
in 6 rounds
- Latest Funding Round$480K (USD), Debt – Conventional
Sep 2025
Products & Services of Immutrix Therapeutics
Immutrix Therapeutics offers a comprehensive portfolio of products and services, including Blood-Cleansing Device and Extracorporeal System.
Device removes harmful molecules from blood to treat medical conditions.
System modulates blood components for rapid-response disease treatment.
Funding Insights of Immutrix Therapeutics
Immutrix Therapeutics has successfully raised a total of $14.02M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $480 thousand completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.02M
- Total Rounds 6
- Last Round Debt – Conventional — $480,000
- First Round $3.9M
(Oct 2015)
All 6 funding rounds of Immutrix Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $480,000 | Debt – Conventional | – | – | – |
| Jul 2020 | $300,000 | Series A | – | – | – |
| Sep 2019 | $450,000 | Series A | – | – | – |
| Oct 2018 | $5.28M | Series A | – | – | – |
| Jul 2016 | $4.09M | Series A | – | – | – |
| Oct 2015 | $3.9M | Series A | – | – | – |
People of Immutrix Therapeutics
5 people are tracked at Immutrix Therapeutics (5 in leadership).
| Name | Role | Group |
|---|---|---|
Carol Rae | Founder & CEO | Leadership |
Ronald L Shape | CEO & CFO | Leadership |
Jose A. Aunon Diaz | VP of Technical & Business Development | Leadership |
Jeff Barnes | VP of Technology & Product Development | Leadership |
Steve Ford | VP of Sales | Leadership |
Complete people profiles for Immutrix Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Immutrix Therapeutics
3 dated milestones of Immutrix Therapeutics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Immutrix Therapeutics is founded.
- Funding First funding round of $3.9M.
- Funding Latest funding round, Debt – Conventional, of $480K.
Competitors of Immutrix Therapeutics
Immutrix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, MediSieve, Hemostasis and Immunocept Medical Products, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| haemonetics.com | 1971 | Braintree, United States | – | 3,034 | Hematology products and solutions are provided for medical applications. | |
| vetexmedical.com | 2016 | Galway, Ireland | – | – | Catheters for venous clot management and removal are developed. | |
| medisieve.com | 2014 | London, United Kingdom | $4.18M | 12 | Magnetic therapy is developed to treat blood-borne diseases. | |
| hemostasisllc.com | 2006 | Saint Paul, United States | – | – | Develops and manufactures hemostatic products for surgical bleeding control and patient care. | |
| immunocept.com | 1999 | Denver, United States | $530,000 | – | Blood filtration therapy for severe sepsis is developed. | |
| straubmedical.com | 1997 | Vilters Wangs, Switzerland | – | – | Medical devices for treating peripheral vascular diseases are developed. | |
| fiveliters.com | 2022 | Dallas, United States | $500,000 | – | Developer of medical device for non-invasive neuromodulation of hemorrhaging | |
| exvivodynamics.com | 2013 | New York, United States | – | – | Microparticles are filtered from stored blood for transfusion safety. |
Detailed competitors of Immutrix Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Immutrix Therapeutics
10 companies that operate in the same segment as Immutrix Therapeutics (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immutrix Therapeutics
Immutrix Therapeutics was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Immutrix Therapeutics is headquartered in Rapid City, United States. It is registered at Rapid City, South Dakota, United States.
Carol Rae is the current CEO of Immutrix Therapeutics. They have also founded this company.
Immutrix Therapeutics is a funded company, having raised a total of $14.02M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3.9M, raised on Oct 2015.
Immutrix Therapeutics develops blood cleansing treatment device. It removes inflammatory mediators and toxins from blood using proprietary adsorbents and smart hollow fiber membranes. It cleanses whole blood to modulate and sequester molecules from circulation. It targets and binds molecules to treat a broad range of medical conditions.
Immutrix Therapeutics's top competitors include Haemonetics, Vetex Medical and MediSieve.
Immutrix Therapeutics offers Blood-Cleansing Device and Extracorporeal System.
Immutrix Therapeutics operates through Immutrix Therapeutics, Inc..